Analysts see impact on CSL's operations on possible US pharma tariffs

Analysts at UBS and Bell Potter say they expect pharmaceutical firm CSL CSL.AX to be impacted if U.S. tariffs take hold

U.S. President Trump said that pharmaceutical imports, currently exempt from tariffs, will face "major" levy soon

"We would not be surprised to see incentives for moving production over the coming years, if not immediately" - UBS; maintains PT of A$310, rated 'Buy'

Bell Potter expects some impact on CSL given fractionation of CSL Behring's plasma-derived products across Australia, Germany, Switzerland and the U.S

CSL shares last up 2.5% at A$238.94, in line with broadly positive market sentiment .AX

YTD, CSL down 10.9%